Abstract
purpose. To investigate long-term changes in the anterior segment of primate eyes treated for one year with different prostaglandin agonists and a prostamide. The results were compared with those obtained after vehicle treatment and in untreated controls.
methods. Sixteen young cynomolgus monkeys were unilaterally topically treated for 1 year with either bimatoprost 0.03% (prostamide), sulprostone 0.03% (EP3/EP1 agonist), AH13205 0.1% (EP2 agonist), or latanoprost 0.005% (FP agonist), which all lower IOP in this species at the doses applied. Four animals were treated with the vehicle only. In all cases the left eye was treated, the right eye remained untreated. Six monkeys served as untreated controls. Sections from 4 quadrants each of the circumference of the eyes of 16 drug-treated, 4 vehicle-treated and 6 untreated control animals were investigated qualitatively and quantitatively using light- and electronmicroscopy. The area of widened spaces between ciliary muscle bundles, the number of nerve fiber bundles at the muscle tips, and the width and length of the ciliary muscle were quantitated.
results. The general morphology of the ciliary muscle and trabecular meshwork was normal in appearance and shape in all animals, whereas some localized morphologic changes were observed in the drug-treated animals. The changes were found to be similar in all four treatment groups. In the ciliary muscle, there was a significant increase in optically empty spaces between muscle bundles in the anterior portion of the longitudinal and the reticular ciliary muscle compared with untreated and vehicle-treated control animals. Within these spaces, significantly more myelinated nerve fiber bundles were found in drug-treated compared with normal control animals. Ultrastructurally the spaces were partly covered by endothelial-like cells which, in some areas, were in contact with the basement membrane of the microvasculature. In all treatment groups, there were also changes in the trabecular meshwork region. Significant regional differences among the different quadrants of the eyes and quantitative differences between treatment groups were observed. The ciliary epithelium had a normal appearance in all treatment groups.
conclusions. After one year of treatment with different prostaglandins and a prostamide, uveoscleral outflow pathways are enlarged and appear organized. Conventional outflow routes were also affected. Long-term treatment with AH13205, latanoprost, sulprostone, or bimatoprost also induces sprouting of nerve fibers.
It is well established that topical treatment with prostaglandin (PG) F
2α lowers intraocular pressure due to enlargement of uveoscleral outflow pathways.
1 2 3 The mechanism underlying this effect is still not fully understood. First, ultrastructural studies by Tamm et al. showed that after 5 days of treatment with PGF
2α there were signs of lysis of extracellular matrix (ECM) components between ciliary muscle (CM) bundles and widening of the intermuscular spaces.
4 Lindsey et al.
5 using immunohistochemical methods found that collagens type I, III, and IV were reduced in monkey eyes treated with PGF
2α for 5 days and that matrix metalloproteinases (MMP) 1, 2, and 3 were increased. The authors suggested that PGF
2α may regulate uveoscleral outflow by MMP mediated alterations in CM matrix metabolism.
6 All these studies however, were performed after short-term treatment with PGF
2α for up to 5 days. Whether the long-term IOP effect of the drug is due to the same mechanism remains unknown. In a preliminary study, Svedbergh et al. investigated the histologic changes in aphacic cynomolgus monkey eyes treated with latanoprost (0.035%, once daily) for 6 months.
7 These authors did not see any differences in morphology between latanoprost and vehicle-treated eyes or between treated and untreated control monkeys. Unfortunately, the data are presented only in an ARVO Abstract so that the detailed descriptions of the materials and methods, e.g., the methods for handling the eyes after enucleation and the exact results are not available.
In the present study we investigated the morphologic changes in the anterior eye segment of cynomolgus monkeys unilaterally treated with the prostaglandin analogs sulprostone (EP
1/EP
3 agonist),
8 AH13205 (EP
2 agonist),
9 latanoprost (FP agonist prodrug),
10 and the prostamide bimatoprost
11 for 1 year using qualitative and quantitative light- und electronmicroscopy as well as immunohistochemistry. These drugs were chosen because they lower IOP in this species at the concentration selected, while principally acting via different receptors.
11 12 13 14 15 16 On a second messenger level, these receptors are known to stimulate (EP
2) or inhibit (EP
3) cAMP formation, or elevate intracellular calcium (EP
1, FP, prostamide). We sought to investigate the long-term effects of these pharmacologically distinct ocular hypotensive drugs on tissues associated with aqueous humor outflow. The morphologic qualitative and quantitative investigation of the eyes was performed for all four treatment groups together, in a masked fashion, by two independent observers. Because morphologic changes were also seen in the untreated contralateral eyes in all treatment groups, the data were compared with those obtained from untreated and vehicle-treated matched control animals.
Sixteen cynomolgus monkeys (Macaca fascicularis), divided into four treatment groups of four animals each, were topically treated once daily for 1 year with either bimatoprost 0.03% (AGN192024), sulprostone 0.03%, AH13205 0.1%, or latanoprost 0.005%. In previous studies it has been demonstrated that these drugs lower IOP at the concentrations selected. The animals were unilaterally treated in the left eye; the right eye remained untreated. Six untreated and four vehicle-treated (poloxamer) animals were used as controls. The drug was delivered in a 25-μL volume using a micropipette to conscious, chair-restrained animals. The eyes were examined ophthalmologically at the beginning of the experiment and after 3, 6, 9 and 12 months by a veterinarian ophthalmologist. No pathologic changes were observed. All animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
The Ito-fixed eyes were rinsed in cacodylate buffer. The specimens were postfixed in 1% OsO4, dehydrated in an ascending series of alcohols, and embedded in resin (Epon; Fa Roth, Karlsruhe, Germany) according to standard methods. Semithin sections were cut using a microtome (Ultracut OmU3; Reichert, Vienna, Austria) and stained with toluidine blue. Ultrathin sections were stained with uranylacetate and lead citrate and viewed in an electron microscope (EM 902; Carl Zeiss, Oberkochen, Germany). From each quadrant of the eye ∼20 semithin sections were analyzed qualitatively. Because the changes within adjacent areas of one quadrant were similar, the best section (one section without folds and clean staining) of each quadrant was used for quantitative evaluation.
For each treatment group, quantitative evaluation of the area of enlarged intermuscular spaces and the length and width of the CM was performed on sagittally orientated semithin sections. Measurements were obtained from one section of each of the four quadrants of the circumference of the treated eyes and the respective contralateral eyes, fixed as described above. Quantitative measurement of the widened spaces in the CM was performed with a PC-based morphometric system (Quantimet 500; Leica, Cambridge, UK), in a masked fashion by two persons independently in a measuring window of ∼200,000 μm
2 (333 × 600 μm) at a magnification of ×400.
Figure 1 demonstrates the location of the measurement window. The data obtained by the two observers were so similar that the data obtained by the first author are listed in the tables.
Widening of intermuscular spaces could increase the width of the anterior CM. Therefore, measurement of the width (perpendicular distance between inner apex and outer longitudinal edge) of the CM was performed in each quadrant at a magnification of ×30 using a drawing microscope (Model 43463; Wild, Heersbrugg, Switzerland), as schematically depicted in
Figure 1 and described in a previous paper.
18 The width of the CM is also increased in the event of a contractile response. CM contraction, in addition to increasing the CM width, concomitantly decreases the length of the muscle.
18 To distinguish whether the observed increase in CM width was the result of a widening of intermuscular spaces or a contraction of the muscle, the length of the CM (anteroposterior distance from the posterior tip to the anterior insertion of the scleral spur) was also determined.
The number of nerve fiber bundles was counted in the longitudinal, reticular, and circular portions in the most anterior part of the CM in each quadrant in a measurement field of approximately 200,000 μm
2 (magnification ×400); the same field as used for the measurement of the enlarged spaces
(Fig. 1) . The number of nerve fiber bundles was determined in each quadrant of each eye and averaged separately for the longitudinal/reticular and circular portions of the CM.
Ciliary Body.
Ciliary Muscle.
Ciliary Processes.
Trabecular Meshwork.
Our study demonstrates that, despite the different pharmacological profiles of the drugs investigated, long-term treatment for 1 year resulted in enlarged intermuscular spaces in the ciliary body, presumably representing uveoscleral outflow routes. This observation was made for all four ocular hypotensive drugs: one prostamide and three pharmacologically selective prostaglandin analogs. Widening of intermuscular spaces, quantified directly using light microscopy, was accompanied by an increase in CM width without concomitant decrease in length. Based on these findings, it appears that the increase in width was caused by a widening of the intermuscular spaces and was not the result of a potential contraction of the CM. Histologically the spaces were small such that the general morphology of the CM of animals treated for one year was similar in appearance and shape to normal untreated animals.
In contrast to our findings in animals treated with high doses of PGF
2α -isopropylester for 5 days,
3 in the present study we did not find macrophages at the muscle tips or in the intermuscular spaces, but the spaces appeared more organized than in the short-term treated eyes. The fluid pathways appeared lined by an incomplete layer of EEC similar to fluid pathways in the choroid. In the choroid such pathways have been discussed as a kind of lymphatic.
20 Because the entire ciliary muscle is formed by a three-dimensional network of connected branching muscle cells, elongated tube like spaces are never seen in normal eyes in this region of the muscle.
19 Therefore, remodeling of the intermuscular connections and subsequent organization of fluid flow pathways would best explain our findings.
In the CM of the treated eyes these pathways seemed to lead toward capillaries present within the enlarged spaces. Because only fluid will enter the microvessels, it is possible that particles within the aqueous are scavenged in the basement membrane, thereby leading to the observed thickening. In vitro studies by Ocklind
21 and Lindsey et al.
22 suggested that the increase in the width of the intermuscular spaces leading to an increase in uveoscleral outflow may be the consequence of a stimulation of MMP synthesis by CM cells in response to treatment with prostaglandin F
2α. If this is also true for treatment with bimatoprost, AH13205, and sulprostone, such synthesis of MMPs might still be elevated after long-term treatment. Alternatively, the pathways may not be constantly reformed but may be established initially, remain open, and then become organized as a result of fluid flow. It is interesting to note that long-term treatment with the drugs used in this study did not lead to a posterior extension of the fluid pathways beyond what is already visible after short-term treatment with PGF
2α-isopropylester for 5 days.
3 Thus, remodeling of the ECM in response to these drugs is restricted to longitudinal and reticular portions of the CM. While these fluid pathways appear to form rather rapidly, long-term treatment does not lead to an extension of the channels but to better organization.
In our study we also found changes in the conventional outflow routes. These changes were not present in all parts of the circumference of the eyes, but in areas where they were prominent, loss of ECM components could have been induced by MMPs similar to what has been suggested for the CM. Trabecular cells bridging gaps and covering partly missing trabecular beams indicate that there are also repair mechanisms and organization of fluid pathways in the conventional outflow routes. In monkey eyes loss of ECM from the cribriform region and disconnection of the cells from the ECM leads to extension of the inner wall with increase in conventional outflow.
23 24 On the other hand, SC is partly collapsed. Because this collapse shows circumferential variations, it is difficult to predict whether treatment with any of these compounds induced changes in conventional outflow in our monkey eyes as a net effect.
Widening of intermuscular spaces and loss of extracellular material in parts of the circumference of the TM was also found in animals treated with the PGE
2 analogs sulprostone (EP
1/EP
3 agonist) and AH13205 (EP
2 agonist). In vitro treatment of CM cells with 11-deoxy-PGE
1, a nonspecific PGE
2 analog, increases production of MMP 1, 2, 3 and 9.
25 It is, therefore, not unreasonable to assume that the widening of spaces in the anterior part of the CM seen in eyes treated with sulprostone and AH13205 is induced by a similar mechanism.
After prostamide and prostaglandin treatment, the changes were significantly different from those found after long-term treatment with other classes of IOP-lowering drugs. After long-term treatment with the β-blocker timolol and after treatment with epinephrine-pronounced changes in the ciliary processes were seen.
26 In none of the animals investigated in this study were changes in the ciliary epithelium observed. The morphology of the trabecular meshwork was also completely different after long-term treatment with the prostamide and prostaglandin analogs compared with long-term treatment with other antiglaucoma drugs. The rarefication of the trabecular meshwork was much more prominent in timolol-treated eyes. On the other hand, after long-term treatment with pilocarpine or phospholin iodide in monkeys, there was an increase in ECM in the cribriform region which was not seen in the treatment groups of this study.
26 27 28
In all treatment groups the contralateral-untreated eyes showed similar morphologic changes in the CM and TM as the treated eyes. Contralateral effects had also been observed in animals treated long-term with timolol, epinephrine, pilocarpine, and phospholiniodid.
26 27 28 This could be due to a contralateral contamination but more likely results from systemic absorption. Even if the drugs used in this study might be more quickly metabolized than the other drugs, rapid diffusion and active transport of active drug into ocular tissues from the systemic simulation is a distinct possibility.
An unexpected finding in all treatment groups was the increase in nerve fiber bundles in the longitudinal and reticular portion of the CM and TM. In the muscle the increased nerve fiber bundles were especially numerous at places where the intermuscular spaces were enlarged. The mechanism underlying this sprouting of nerve fibers is not yet known. It is possible that a retrograde degeneration of nerve fibers induces sprouting. Alternatively, these drugs may act as neurotrophic factors themselves. However, further studies are needed to clarify this.
In conclusion, long-term treatment with different prostaglandins and a prostamide leads to an enlargement of uveoscleral outflow routes and to morphologic changes in the TM perhaps suggestive of increased uveoscleral and conventional outflow. In the affected CM areas, sprouting of nerve fibers may be the consequence of tissue remodeling. The finding that the four drugs investigated, which are all ocular hypotensive agents in the same species but principally act through different receptors, produced similar changes in the aqueous outflow routes was not quite expected. To determine whether these actions involve a final common or parallel pathways requires further investigation.
Supported by Interdisziplinaeres Zentrum Klinischer Forschung (IZKF), Erlangen, Germany, and Sonderforschungsbereich (SFB) 539 of the Deutsche Forschungsgemeinschaft, Bonn, Germany.
Submitted for publication December 13, 2002; revised May 27, 2003; accepted June 16, 2003.
Disclosure:
M. Richter, None;
A.H.-P. Krauss, Allergan (E);
D.F. Woodard, Allergan (E);
E. Lütjen-Drecoll, Allergan (F)
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Elke Lütjen-Drecoll, Department of Anatomy II, Universitätsstraße 19, 91054 Erlangen, Germany;
[email protected].
Table 1. Area of Empty Spaces in the Longitudinal and Reticular Portion of the Ciliary Muscle
Table 1. Area of Empty Spaces in the Longitudinal and Reticular Portion of the Ciliary Muscle
Drug | Treated Eye (μm2) | Contralateral Eye (μm2) |
Bimatoprost | 9408 ± 4276* | 9414 ± 2470* |
| (3227–19153) | (7166–13134) |
AH13205 | 9252 ± 3523* | 6393 ± 2696* |
| (5433–19085) | (1562–11581) |
Sulprostone | 7263 ± 4074* | 8808 ± 2518* |
| (3382–18868) | (4824–14461) |
Latanoprost | 8465 ± 4656* | 11900 ± 8666* |
| (2857–18683) | (2682–27757) |
Vehicle | 3103 ± 1190 | 3139 ± 943 |
| (734–4401) | (1160–4873) |
Untreated | 2536 ± 1240 | |
| (1056–4314) | |
Table 2. Length and Width of the Ciliary Muscle
Table 2. Length and Width of the Ciliary Muscle
Drug | Length (μm) | | Width (μm) | |
| Treated Eye | Contralateral Eye | Treated Eye | Contralateral Eye |
Bimatoprost | 2277.5 ± 263.3 | 2299.1 ± 260.1 | 757.9 ± 111.4* | 773.0 ± 91.2* |
AH13205 | 2069.8 ± 205.1 | 2067.2 ± 230.9 | 718.3 ± 59.6* | 741.5 ± 60.6* |
Sulprostone | 2336.2 ± 380.3 | 2083.9 ± 237.2 | 685.6 ± 61.0* | 693.3 ± 87.3* |
Latanoprost | 2089.0 ± 271.3 | 2217.6 ± 403.8 | 866.4 ± 82.5* | 881.4 ± 146.3* |
Vehicle | 2192.9 ± 275.1 | 2130.1 ± 248.9 | 539.7 ± 76.0 | 539.7 ± 65.5 |
Untreated | 2192.1 ± 261.8 | | 634.0 ± 133.7 | |
Table 3. Number of Nerve Bundles in the Longitudinal and Reticular Portion of the Ciliary Muscle
Table 3. Number of Nerve Bundles in the Longitudinal and Reticular Portion of the Ciliary Muscle
Drug | Treated Eye (n) | Contralateral Eye (n) |
Bimatoprost | 10.50 ± 2.15* | 10.00 ± 1.83* |
AH13205 | 9.81 ± 2.43* | 8.43 ± 1.95* |
Sulprostone | 10.57 ± 1.95* | 10.00 ± 1.58* |
Latanoprost | 9.53 ± 2.03* | 9.60 ± 2.39* |
Vehicle | 5.25 ± 2.38 | 4.47 ± 2.06 |
Untreated | 5.70 ± 2.43 | 5.70 ± 2.43 |
Table 4. Number of Nerve Bundles in the Circular Portion of the Ciliary Muscle
Table 4. Number of Nerve Bundles in the Circular Portion of the Ciliary Muscle
Drug | Treated Eye (n) | Contralateral Eye (n) |
Bimatoprost | 2.00 ± 0.97 | 2.94 ± 1.56 |
AH13205 | 2.50 ± 0.91 | 2.75 ± 0.90 |
Sulprostone | 2.94 ± 1.25 | 2.57 ± 0.82 |
Latanoprost | 2.60 ± 0.95 | 3.13 ± 1.02* |
Vehicle | 2.67 ± 0.79 | 2.33 ± 0.88 |
Untreated | 2.20 ± 1.03 | 2.20 ± 1.03 |
Table 5. Summary of Morphological Changes Observed in Trabecular Meshwork and Schlemms Canal
Table 5. Summary of Morphological Changes Observed in Trabecular Meshwork and Schlemms Canal
Category | Treated Eye (%) | | | Contralateral Eye (%) | | |
| 1 | 2 | 3 | 1 | 2 | 3 |
Controls | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 |
Vehicle | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 |
Bimatoprost | 13.3 | 66.7 | 20.0 | 20.0 | 80.0 | 0.0 |
Sulprostone | 15.1 | 46.1 | 38.8 | 33.3 | 33.3 | 33.3 |
AH13205 | 25.0 | 37.5 | 37.5 | 7.7 | 38.5 | 53.8 |
Latanoprost | 20.0 | 26.7 | 53.3 | 25.0 | 37.5 | 37.5 |
The authors thank Anke Fischer, Gertie Link, and Heide Wiederschein for their excellent technical assistance and Marco Gößwein, who expertly prepared the micrographs. The authors would also like to thank Teresa Guerra for expert veterinary assistance and examinations of the study animals.
Nilsson, SFE, Samuelsson, M, Bill, A, Stjernschantz, J. (1989) Increased uveoscleral outflow as a possible mechanism of ocular hypertension caused by prostaglandin F
2α-1-isopropylester in the cynomolgus monkey Exp Eye Res 48,707-716
[CrossRef] [PubMed]Crawford, K, Kaufman, PL. (1987) Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha Arch Ophthalmol 105,1112-1116
[CrossRef] [PubMed]Lütjen-Drecoll, E, Tamm, E. (1988) Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F
2α Exp Eye Res 47,761-769
[CrossRef] [PubMed]Tamm, E, Lütjen-Drecoll, E, Rohen, JW. (1990) Age-related changes in the ciliary muscle in comparison with changes induced by treatment with prostaglandin F
2α. An ultrastructural study in rhesus and cynomolgus monkeys Mech Ageing Dev 51,101-120
[CrossRef] [PubMed]Lindsey, JD, Weinreb, RN. (1998) Effects of prostaglandins on uveoscleral outflow Alm, A Weinreb, RN eds. Uveoscleral Outflow, Biology and Clinical Aspects ,41-55 Mosby International London.
Lindsey, JD, Kashiwagi, K, Boyle, D, Kashiwagi, F, Firestein, GS, Weinreb, RN. (1996) Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells Curr Eye Res 15,869-875
[CrossRef] [PubMed]Svedbergh, B, Forsberg, I. (1993) A morphological study on the effects of chronic administration of latanoprost (LP) on the ciliary muscle and trabecular meshwork in monkeys Invest Ophthalmol Vis Sci 34,A1152-A1168
Coleman, RA, Kennedy, I, Sheldrick, RLG. (1987) New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors Adv PG Tx Lt Res 17,467-470
Nials, AT, Vardey, CJ, Denyer, LH, et al (1993) AH13205, a selective prostanoid EP
2 receptor agonist Cardiovasc Drug Rev 11,165-179
[CrossRef] Stjernschantz, J. (2001) From PGF
2α-1-isopropyl ester to latanoprost: a review of the development of Xalatan Invest Ophthalmol Vis Sci 42,1134-1145
[PubMed]Woodward, DF, Krauss, AH-P, Chen, J, et al (2001) The pharmacology of bimatoprost (Lumigan™) Surv Ophthalmol 45,S337-S345
[CrossRef] [PubMed]Woodward, DF, Krauss, AH-P, Chen, J, et al (2003) Pharmacological characterization of a novel anti-glaucoma agent, bimatoprost (AGN 192024) J Pharmacol Exp Ther 305,772-785
[CrossRef] [PubMed]Stjernschantz, J, Resul, B. (1992) Phenyl substituted prostaglandin analogs for glaucoma treatment Drugs Future 17,691-704
[CrossRef] Woodward, DF, Bogardus, AM, Donello, JE, et al (1995) Molecular characterization and ocular hypotensive properties of the prostanoid EP
2 receptor J Ocular Pharmacol Ther 11,447-454
[CrossRef] Woodward, DF, Lawrence, RA, Fairbairn, CE, Shan, T, Williams, LS. (1993) Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies J Lipid Med 6,545-553
Woodward, DF, Chan, MF, Burke, JA, et al (1994) Studies on the ocular hypotensive effects of prostaglandin F
2α ester prodrugs and receptor selective prostaglandin analogs J Ocular Pharmacol Ther 10,177-193
[CrossRef] Ito, S, Karnovsky, MJ. (1968) Formaldehyde-glutaraldehyde fixatives containing trinitro compounds J Cell Biol 39,168a
Lütjen-Drecoll, E, Tamm, E, Kaufman, PL. (1988) Age-related loss of morphologic responses to pilocarpine in rhesus monkey ciliary muscle Arch Ophthalmol 106,1591-1598
[CrossRef] [PubMed]Tamm, ER, Lütjen-Drecoll, E. (1996) Ciliary body Microscopy Research and Technique 33,390-439
[CrossRef] [PubMed]Krebs, W, Krebs, IP. (1988) Ultrastructural evidence for lymphatic capillaries in the primate choroid Arch Ophthlamol 106,1615-1616
[CrossRef] Ocklind, A. (1998) Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections Exp Eye Res 67,179-191
[CrossRef] [PubMed]Lindsey, JD, Kashiwagi, K, Kashiwagi, F, Weinreb, RN. (1997) Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow Surv Ophthalmol 42,S53-S59
Lütjen-Drecoll, E, Svedbergh, B, Ober, M, Kaufmann, PL. (1978) Cytochalasin B-induced structural changes in the anterior ocular segment of the cynomolgus monkey Invest Ophthalmol Vis Sci 17,718-734
[PubMed]Bill, A, Lütjen-Drecoll, E, Svedbergh, B. (1980) Effect of intracameral Na2 EDTA and EGTA on aqueous outflow routes in monkey eyes Invest Opthalmol Vis Sci 19,492-504
Weinreb, RN, Mitchell, MD. (1989) Prostaglandin production by cultured cynomolgus monkey trabecular meshwork cells Prostaglandins Leukot Essent Fatty Acids 36,97-100
[CrossRef] [PubMed]Lütjen-Drecoll, E, Kaufman, PL, Eichhorn, M. (1986) Long-term timolol and epinephrine in monkeys. I. Functional morphology of the ciliary processes Trans Ophthalmol Soc UK 105,180
[PubMed]Lütjen-Drecoll, E, Wiendl, H, Kaufman, PL. (1998) Acute and chronic structural effects of pilocarpine on monkey outflow tissues Tr Am Ophth Soc XCVI,171-195
Lütjen-Drecoll, E, Kaufman, PL. (1979) Echothiophate-induced structural alterations in the anterior chamber angle of the cynomolgus monkey Invest Ophtahlmol Vis Sci 18,918-929